Teacher Retirement System of Texas Purchases Shares of 9,070 Regenxbio Inc (RGNX)
Teacher Retirement System of Texas purchased a new position in shares of Regenxbio Inc (NASDAQ:RGNX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 9,070 shares of the biotechnology company’s stock, valued at approximately $302,000.
A number of other institutional investors also recently added to or reduced their stakes in RGNX. The Manufacturers Life Insurance Company lifted its position in Regenxbio by 34.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,817 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 5,627 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Regenxbio during the 3rd quarter worth approximately $463,000. Jane Street Group LLC acquired a new position in Regenxbio during the 3rd quarter worth approximately $476,000. SG Americas Securities LLC acquired a new position in Regenxbio during the 3rd quarter worth approximately $619,000. Finally, Ipswich Investment Management Co. Inc. acquired a new position in Regenxbio during the 4th quarter worth approximately $728,000. 69.22% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Curran Simpson sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $33.00, for a total value of $825,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kenneth T. Mills sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $27.33, for a total value of $273,300.00. Following the completion of the sale, the insider now owns 248,530 shares of the company’s stock, valued at $6,792,324.90. The disclosure for this sale can be found here. Insiders sold a total of 60,000 shares of company stock valued at $1,810,200 over the last quarter. Company insiders own 17.00% of the company’s stock.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.20. Regenxbio had a negative return on equity of 36.48% and a negative net margin of 704.02%. The company had revenue of $2.04 million for the quarter. sell-side analysts anticipate that Regenxbio Inc will post -2.44 EPS for the current year.
Several equities research analysts have issued reports on the company. BidaskClub downgraded Regenxbio from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Morgan Stanley dropped their price objective on Regenxbio from $36.00 to $35.00 and set an “overweight” rating on the stock in a report on Wednesday, March 14th. Zacks Investment Research downgraded Regenxbio from a “buy” rating to a “hold” rating in a report on Saturday, March 10th. Mizuho assumed coverage on Regenxbio in a report on Monday, February 12th. They set a “neutral” rating and a $28.00 price objective on the stock. Finally, TheStreet downgraded Regenxbio from a “c” rating to a “d+” rating in a report on Tuesday, November 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $40.63.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/teacher-retirement-system-of-texas-purchases-shares-of-9070-regenxbio-inc-rgnx/1960030.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.